Stockscreener 앱 받기
1.58
3.28%
-0.1429
전일 마감가:
$1.4371
열려 있는:
$1.48
하루 거래량:
49,376
Relative Volume:
3.08
시가총액:
$51.01M
수익:
-
순이익/손실:
$-41.36M
주가수익비율:
-0.9634
EPS:
-1.64
순현금흐름:
$-42.09M
1주 성능:
-1.41%
1개월 성능:
+8.59%
6개월 성능:
-39.04%
1년 성능:
-44.18%
1일 변동 폭
$1.375
$1.69
1주일 범위
$1.29
$1.69
52주 변동 폭
$0.8981
$3.45
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
명칭
Armata Pharmaceuticals Inc
전화
310-655-2928
주소
4503 Glencoe Avenue, Marina del Rey, CA
ARMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
1.53 | 51.01M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.17 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.85 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
657.08 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.26 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.95 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-19 | 개시 | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc 주식(ARMP)의 최신 뉴스
Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World
Armata Pharmaceuticals secures additional DoD funding - Investing.com
Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
New Strong Sell Stocks for April 28th - The Globe and Mail
10 Best Healthcare Stocks to Invest In (May 2025) - Securities.io
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World
Bacteriophage Therapy Market Future Business Opportunities - openPR
HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World
Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN
Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire
Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter
Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia
Armata Pharmaceuticals secures $10 million credit - Investing.com India
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - Quantisnow
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5% - MarketBeat
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 203.3% - MarketBeat
Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca - The Globe and Mail
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire
Armata Pharmaceuticals (STU:TG1N) PS Ratio : (As of Jan. 14, 2025) - GuruFocus.com
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
Armata Pharmaceuticals Announces $35 Million Secured Credit Agre - GuruFocus.com
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 125.9% - MarketBeat
Ampliphi Biosciences (NYSEAMERICAN:APHB) Announces Positive Results from Phase 2 Tailwind Study - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns “Buy” Rating from HC Wainwright - Defense World
Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study - Yahoo Finance
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given Buy Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Reports Positive Phase 2 Study Results - TipRanks
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire
ARMP Stock Touches 52-Week Low at $1.98 Amid Market Challenges - Investing.com
Suparna Mishra Sarkar - Los Angeles Times
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - The Eastern Progress Online
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - The Eastern Progress Online
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - The Eastern Progress Online
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit - GuruFocus.com
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Armata Pharmaceuticals Inc (ARMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):